{"filing":{"accession_number":"0001140361-26-022979","cik":"0001743881","ticker":"BBIO","company_name":"BridgeBio Pharma, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"ef20074977_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1743881/000114036126022979/ef20074977_8k.htm"},"events":[{"id":8694,"run_id":7633,"accession_number":"0001140361-26-022979","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"BridgeBio announced FDA acceptance and priority review of an NDA for BBP-418, a significant regulatory milestone for a drug candidate. While this is a material event affecting investor assessment of the company's pipeline progress and regulatory prospects, it does not fit neatly into the more specific event categories (it is neither an earnings release, executive change, M\u0026A activity, nor a negative event like impairment or litigation). This is best classified as other_material.","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1854,"accession_number":"0001140361-26-022979","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"BridgeBio announced FDA acceptance and priority review of an NDA for BBP-418, a significant regulatory milestone for a drug candidate. While this is a material event affecting investor assessment of the company's pipeline progress and regulatory prospects, it does not fit neatly into the more specific event categories (it is neither an earnings release, executive change, M\u0026A activity, nor a negative event like impairment or litigation). This is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:11:26.195924+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1854,"accession_number":"0001140361-26-022979","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"BridgeBio announced FDA acceptance and priority review of an NDA for BBP-418, a significant regulatory milestone for a drug candidate. While this is a material event affecting investor assessment of the company's pipeline progress and regulatory prospects, it does not fit neatly into the more specific event categories (it is neither an earnings release, executive change, M\u0026A activity, nor a negative event like impairment or litigation). This is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:11:26.195924+00:00","company_name":"BridgeBio Pharma, Inc.","ticker":"BBIO","filing_date":"2026-05-27"}]}